[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$feZFHLjH4RuDmlNupvb08b6McShvzdA_GM3dLf3r3XFQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":82,"rows":89},"Betta Pharmaceuticals Co., Ltd.",[4],75,false,14,10,8700,18,0,[14,17,19,22,24,26,29,31],{"name":15,"count":16},"Non-small Cell Lung Cancer",17,{"name":18,"count":9},"Non-Small Cell Lung Cancer",{"name":20,"count":21},"Brain Metastases",5,{"name":23,"count":21},"NSCLC",{"name":25,"count":21},"Solid Tumor",{"name":27,"count":28},"EGFR Positive Non-small Cell Lung Cancer",4,{"name":30,"count":28},"Adenocarcinoma",{"name":32,"count":33},"Non-small-cell Lung Cancer",3,[35,40,45,50,54,59,64,69,74,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06492525","A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers","2024-10","Ensartinib",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05007938","Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer","2024-12-31","Icotinib",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05789602","A Study of BPI-460372 in Advanced Solid Tumor Patients","2025-04-17","BPI-460372",{"nctId":51,"briefTitle":52,"date":53,"intervention":39},"NCT05341583","Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer","2025-06-01",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT03791112","A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor","2025-12","BPI-16350",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06641609","A Phase I Study of CFT8919 in Patients With Advanced NSCLC","2025-12-09","Dose-Escalation (Phase Ia) CFT8919",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05341557","A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed\u002FRefractory Lymphoma","2026-12","BPI-371153",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06885840","Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.","2028-04","MCLA-129",{"nctId":75,"briefTitle":76,"date":77,"intervention":73},"NCT04930432","Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","2028-04-30",{"nctId":79,"briefTitle":80,"date":77,"intervention":81},"NCT06041776","Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","Befotertinib + Icotinib placebo",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,170,194,212,246,282,554,572,600,640,662,680,698,721,748,766,790,808,826,871,889,907,930,948,970,996,1014,1032,1050,1096,1120,1144,1162,1188,1206,1228,1246,1269,1287,1314,1339,1363,1388,1406,1439,1461,1479,1507,1525,1543,1561,1585,1610,1634,1659,1682,1706,1724,1747,1774,1798],{"intervention":39,"totalTrials":91,"cells":92},6,{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":143,"PHASE3":157,"PHASE4":166,"NA":168},{"trials":94,"activeCount":12},[],{"trials":96,"activeCount":142,"soonestReadout":38},[97,109,120,131],{"nctId":98,"briefTitle":99,"status":100,"phases":101,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":107},"NCT03536481","Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers","COMPLETED",[84],"2019-01-09","2018-06-11",74,[106],"Lung Cancer",[108,108],"ensartinib",{"nctId":36,"briefTitle":37,"status":110,"phases":111,"primaryCompletion":38,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},"NOT_YET_RECRUITING",[84],"2024-12","2024-07",36,[116],"Healthy",[39,118,119,39],"Rifampicin","Itraconazole",{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":126,"start":127,"enrollment":91,"conditions":128,"interventions":130},"NCT03804541","The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human","UNKNOWN",[84],"2019-06","2019-10","2018-12-28",[129],"ALK-POSITIVE NSCLC",[39],{"nctId":132,"briefTitle":133,"status":100,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NCT02959619","Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK",[84],"2019-10-31","2020-04-23","2017-03-06",48,[25,140],"Non-Small Cell Lung Cancer Metastatic",[39],1,{"trials":144,"activeCount":142,"soonestReadout":150},[145],{"nctId":146,"briefTitle":147,"status":148,"phases":149,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":156},"NCT07448116","Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","RECRUITING",[84,85],"2029-02-01","2029-08-01","2026-01-31",164,[155],"Solid Advanced Tumor",[73,39],{"trials":158,"activeCount":142,"soonestReadout":53},[159],{"nctId":51,"briefTitle":52,"status":148,"phases":160,"primaryCompletion":53,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},[86],"2025-07-23","2022-05-24",202,[15],[39],{"trials":167,"activeCount":12},[],{"trials":169,"activeCount":12},[],{"intervention":81,"totalTrials":142,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":190,"NA":192},{"trials":173,"activeCount":12},[],{"trials":175,"activeCount":12},[],{"trials":177,"activeCount":12},[],{"trials":179,"activeCount":142,"soonestReadout":77},[180],{"nctId":79,"briefTitle":80,"status":148,"phases":181,"primaryCompletion":77,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":188},[86],"2029-11-30","2023-03-28",570,[18,186,187],"EGFR Sensitive Mutation","Adjuvant Therapy",[81,189],"Icotinib + Befotertinib placebo",{"trials":191,"activeCount":12},[],{"trials":193,"activeCount":12},[],{"intervention":189,"totalTrials":142,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":208,"NA":210},{"trials":197,"activeCount":12},[],{"trials":199,"activeCount":12},[],{"trials":201,"activeCount":12},[],{"trials":203,"activeCount":142,"soonestReadout":77},[204],{"nctId":79,"briefTitle":80,"status":148,"phases":205,"primaryCompletion":77,"completion":182,"start":183,"enrollment":184,"conditions":206,"interventions":207},[86],[18,186,187],[81,189],{"trials":209,"activeCount":12},[],{"trials":211,"activeCount":12},[],{"intervention":73,"totalTrials":33,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":240,"PHASE4":242,"NA":244},{"trials":215,"activeCount":12},[],{"trials":217,"activeCount":12},[],{"trials":219,"activeCount":33,"soonestReadout":72},[220,229,233],{"nctId":75,"briefTitle":76,"status":148,"phases":221,"primaryCompletion":77,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":228},[84,85],"2028-12-30","2021-09-24",400,[25,18,226,227],"Head and Neck Cancer","Colorectal Cancer",[73],{"nctId":146,"briefTitle":147,"status":148,"phases":230,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":231,"interventions":232},[84,85],[155],[73,39],{"nctId":70,"briefTitle":71,"status":110,"phases":234,"primaryCompletion":72,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":239},[85],"2028-09","2025-03-31",100,[18],[73],{"trials":241,"activeCount":12},[],{"trials":243,"activeCount":12},[],{"trials":245,"activeCount":12},[],{"intervention":247,"totalTrials":248,"cells":249},"Befotertinib",2,{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":276,"PHASE4":278,"NA":280},{"trials":251,"activeCount":12},[],{"trials":253,"activeCount":12},[],{"trials":255,"activeCount":248,"soonestReadout":43},[256,269],{"nctId":257,"briefTitle":258,"status":148,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":267},"NCT07181499","Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI",[85],"2028-11","2028-12","2025-09",28,[23,265,266],"Adjuvant Drug Therapy","EGFR",[247,268],"Pemetrexed + Carboplatin",{"nctId":41,"briefTitle":42,"status":270,"phases":271,"primaryCompletion":43,"completion":43,"start":272,"enrollment":273,"conditions":274,"interventions":275},"ACTIVE_NOT_RECRUITING",[85],"2021-08-12",30,[18],[44,247],{"trials":277,"activeCount":12},[],{"trials":279,"activeCount":12},[],{"trials":281,"activeCount":12},[],{"intervention":44,"totalTrials":283,"cells":284},27,{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":320,"PHASE3":443,"PHASE4":503,"NA":552},{"trials":286,"activeCount":12},[],{"trials":288,"activeCount":12},[289,300,312],{"nctId":290,"briefTitle":291,"status":123,"phases":292,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":298},"NCT02066870","Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI",[84],"2015-09","2016-01","2014-01",9,[15],[44,299],"Arsenic trioxide",{"nctId":301,"briefTitle":302,"status":123,"phases":303,"primaryCompletion":294,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT02278458","Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer",[84],"2016-10","2014-10",24,[308],"Pancreatic Cancer",[310,311],"icotinib","Gemcitabine",{"nctId":313,"briefTitle":302,"status":123,"phases":314,"primaryCompletion":315,"completion":316,"start":317,"enrollment":306,"conditions":318,"interventions":319},"NCT02024633",[84],"2015-12","2016-03","2013-12",[308],[310,311],{"trials":321,"activeCount":142,"soonestReadout":43},[322,331,339,349,358,369,378,387,397,407,419,423,434],{"nctId":323,"briefTitle":324,"status":100,"phases":325,"primaryCompletion":326,"completion":327,"start":295,"enrollment":328,"conditions":329,"interventions":330},"NCT02044328","Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation",[85],"2018-01","2021-10",79,[15],[44],{"nctId":332,"briefTitle":333,"status":123,"phases":334,"primaryCompletion":335,"completion":336,"start":316,"enrollment":273,"conditions":337,"interventions":338},"NCT02726568","High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases",[85],"2021-12","2022-12",[15,20],[44],{"nctId":340,"briefTitle":341,"status":123,"phases":342,"primaryCompletion":343,"completion":344,"start":345,"enrollment":114,"conditions":346,"interventions":348},"NCT03749213","Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer",[85],"2022-02-01","2024-12-30","2018-12-01",[347],"EGF-R Positive Non-Small Cell Lung Cancer",[44],{"nctId":350,"briefTitle":351,"status":123,"phases":352,"primaryCompletion":353,"completion":354,"start":345,"enrollment":355,"conditions":356,"interventions":357},"NCT03754530","Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation",[85],"2020-06-01","2021-12-01",162,[18,20],[44],{"nctId":359,"briefTitle":360,"status":123,"phases":361,"primaryCompletion":343,"completion":362,"start":363,"enrollment":273,"conditions":364,"interventions":368},"NCT03396185","Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer",[85],"2023-02-01","2018-05-09",[365,366,367],"EGFR Gene Mutation","Non Small Cell Lung Cancer Stage IIIA","Non Small Cell Lung Cancer Stage IIIB",[44],{"nctId":370,"briefTitle":371,"status":123,"phases":372,"primaryCompletion":343,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":377},"NCT03349203","Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer",[85],"2023-12-30","2018-10-01",60,[347],[44],{"nctId":379,"briefTitle":380,"status":100,"phases":381,"primaryCompletion":382,"completion":317,"start":383,"enrollment":384,"conditions":385,"interventions":386},"NCT01516983","Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation",[84,85],"2013-06","2011-12",15,[15,20],[310],{"nctId":388,"briefTitle":389,"status":123,"phases":390,"primaryCompletion":304,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":396},"NCT02328261","A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma",[85],"2017-04","2014-11",66,[395],"Nasopharyngeal Carcinoma",[44],{"nctId":398,"briefTitle":399,"status":123,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":237,"conditions":404,"interventions":405},"NCT01843647","Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients",[85],"2016-12","2018-02","2013-04",[32],[44,406],"Chemotherapy",{"nctId":408,"briefTitle":409,"status":100,"phases":410,"primaryCompletion":411,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":418},"NCT01855854","Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH",[85],"2015-08","2016-01-07","2013-05",54,[416,417],"Adenocarcinoma of the Gastroesophageal Junction","Esophageal Carcinoma",[44],{"nctId":41,"briefTitle":42,"status":270,"phases":420,"primaryCompletion":43,"completion":43,"start":272,"enrollment":273,"conditions":421,"interventions":422},[85],[18],[44,247],{"nctId":424,"briefTitle":425,"status":123,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":433},"NCT03346811","Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer",[85],"2019-05-10","2020-03-10","2017-11-18",120,[432],"Plasma EGFR Mutation-positive Lung Cancer",[44],{"nctId":435,"briefTitle":436,"status":123,"phases":437,"primaryCompletion":438,"completion":439,"start":440,"enrollment":273,"conditions":441,"interventions":442},"NCT02062515","Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency",[85],"2016-02","2016-06","2014-02",[15],[310],{"trials":444,"activeCount":12},[445,455,464,474,484,493],{"nctId":446,"briefTitle":447,"status":123,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT04058704","A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy",[86],"2022-12-31","2018-07-20",296,[453,20],"Non Small Cell Lung Cancer",[44],{"nctId":456,"briefTitle":457,"status":100,"phases":458,"primaryCompletion":459,"completion":460,"start":461,"enrollment":451,"conditions":462,"interventions":463},"NCT01719536","Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients",[86],"2016-09","2017-02-07","2012-12",[23],[44,406],{"nctId":465,"briefTitle":466,"status":123,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":473},"NCT02448797","Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation",[86],"2022-06-30","2023-12","2015-06-08",320,[15],[44,406],{"nctId":475,"briefTitle":476,"status":100,"phases":477,"primaryCompletion":478,"completion":383,"start":479,"enrollment":480,"conditions":481,"interventions":482},"NCT01040780","Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients",[86],"2010-03","2009-02",399,[15],[44,483],"Gefitinib",{"nctId":485,"briefTitle":486,"status":100,"phases":487,"primaryCompletion":488,"completion":489,"start":478,"enrollment":490,"conditions":491,"interventions":492},"NCT02486354","Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy",[86],"2011-10","2012-04",128,[15],[310],{"nctId":494,"briefTitle":495,"status":123,"phases":496,"primaryCompletion":497,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":502},"NCT02125240","Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma",[86],"2018-12","2021-07","2014-09",124,[27,30],[44],{"trials":504,"activeCount":12},[505,515,524,533,542],{"nctId":506,"briefTitle":507,"status":123,"phases":508,"primaryCompletion":316,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":513},"NCT02103257","Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB\u002FIV Lung Adenocarcinoma",[87],"2017-09","2014-03",192,[27,30],[514,44],"Sequential Icotinib Plus Chemotherapy",{"nctId":516,"briefTitle":517,"status":100,"phases":518,"primaryCompletion":519,"completion":440,"start":520,"enrollment":521,"conditions":522,"interventions":523},"NCT01465243","Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose",[87],"2013-10","2011-09",32,[15],[44],{"nctId":525,"briefTitle":526,"status":527,"phases":528,"primaryCompletion":315,"completion":401,"start":529,"enrollment":530,"conditions":531,"interventions":532},"NCT01720901","Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy","SUSPENDED",[87],"2013-02",20,[15],[44],{"nctId":534,"briefTitle":535,"status":123,"phases":536,"primaryCompletion":315,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":541},"NCT01646450","First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients",[87],"2016-04","2012-07",35,[18],[44],{"nctId":543,"briefTitle":544,"status":123,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":551},"NCT02404675","High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation",[87],"2017-12","2018-09","2015-04",240,[23],[310],{"trials":553,"activeCount":12},[],{"intervention":268,"totalTrials":142,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":557,"activeCount":12},[],{"trials":559,"activeCount":12},[],{"trials":561,"activeCount":142,"soonestReadout":260},[562],{"nctId":257,"briefTitle":258,"status":148,"phases":563,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":564,"interventions":565},[85],[23,265,266],[247,268],{"trials":567,"activeCount":12},[],{"trials":569,"activeCount":12},[],{"trials":571,"activeCount":12},[],{"intervention":573,"totalTrials":142,"cells":574},"BPI-572270",{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":594,"PHASE4":596,"NA":598},{"trials":576,"activeCount":12},[],{"trials":578,"activeCount":12},[],{"trials":580,"activeCount":142,"soonestReadout":585},[581],{"nctId":582,"briefTitle":583,"status":110,"phases":584,"primaryCompletion":585,"completion":586,"start":587,"enrollment":430,"conditions":588,"interventions":593},"NCT07435038","Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS",[84,85],"2028-12-28","2029-10-28","2026-02-12",[589,590,591,592],"Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Advanced Solid Tumors",[573],{"trials":595,"activeCount":12},[],{"trials":597,"activeCount":12},[],{"trials":599,"activeCount":12},[],{"intervention":58,"totalTrials":33,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":620,"PHASE3":622,"PHASE4":636,"NA":638},{"trials":603,"activeCount":12},[],{"trials":605,"activeCount":142,"soonestReadout":57},[606,612],{"nctId":55,"briefTitle":56,"status":270,"phases":607,"primaryCompletion":57,"completion":57,"start":608,"enrollment":414,"conditions":609,"interventions":611},[84],"2019-07-18",[610],"Advanced Solid Cancer",[58],{"nctId":613,"briefTitle":614,"status":100,"phases":615,"primaryCompletion":616,"completion":616,"start":617,"enrollment":306,"conditions":618,"interventions":619},"NCT05316259","A Food-Effect Study of BPI-16350 in Healthy Subjects",[84],"2022-08-30","2022-04-15",[116],[58],{"trials":621,"activeCount":12},[],{"trials":623,"activeCount":12},[624],{"nctId":625,"briefTitle":626,"status":123,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":634},"NCT05433480","A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer",[86],"2023-12-31","2025-07-31","2022-05-25",274,[633],"Breast Cancer",[58,635],"Fulvestrant",{"trials":637,"activeCount":12},[],{"trials":639,"activeCount":12},[],{"intervention":49,"totalTrials":142,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":643,"activeCount":12},[],{"trials":645,"activeCount":142,"soonestReadout":48},[646],{"nctId":46,"briefTitle":47,"status":148,"phases":647,"primaryCompletion":48,"completion":648,"start":649,"enrollment":650,"conditions":651,"interventions":653},[84],"2026-04-17","2023-04-24",82,[652],"Advanced Solid Tumor",[49],{"trials":655,"activeCount":12},[],{"trials":657,"activeCount":12},[],{"trials":659,"activeCount":12},[],{"trials":661,"activeCount":12},[],{"intervention":118,"totalTrials":142,"cells":663},{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":672,"PHASE3":674,"PHASE4":676,"NA":678},{"trials":665,"activeCount":12},[],{"trials":667,"activeCount":142,"soonestReadout":38},[668],{"nctId":36,"briefTitle":37,"status":110,"phases":669,"primaryCompletion":38,"completion":112,"start":113,"enrollment":114,"conditions":670,"interventions":671},[84],[116],[39,118,119,39],{"trials":673,"activeCount":12},[],{"trials":675,"activeCount":12},[],{"trials":677,"activeCount":12},[],{"trials":679,"activeCount":12},[],{"intervention":119,"totalTrials":142,"cells":681},{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":690,"PHASE3":692,"PHASE4":694,"NA":696},{"trials":683,"activeCount":12},[],{"trials":685,"activeCount":142,"soonestReadout":38},[686],{"nctId":36,"briefTitle":37,"status":110,"phases":687,"primaryCompletion":38,"completion":112,"start":113,"enrollment":114,"conditions":688,"interventions":689},[84],[116],[39,118,119,39],{"trials":691,"activeCount":12},[],{"trials":693,"activeCount":12},[],{"trials":695,"activeCount":12},[],{"trials":697,"activeCount":12},[],{"intervention":68,"totalTrials":142,"cells":699},{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":713,"PHASE3":715,"PHASE4":717,"NA":719},{"trials":701,"activeCount":12},[],{"trials":703,"activeCount":142,"soonestReadout":67},[704],{"nctId":65,"briefTitle":66,"status":148,"phases":705,"primaryCompletion":67,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":712},[84],"2027-04","2022-08-29",110,[652,710,23,711],"Lymphoma","HCC",[68],{"trials":714,"activeCount":12},[],{"trials":716,"activeCount":12},[],{"trials":718,"activeCount":12},[],{"trials":720,"activeCount":12},[],{"intervention":722,"totalTrials":142,"cells":723},"MCLA-129: 1500mg or 2000mg IV Q2W",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":740,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":725,"activeCount":12},[],{"trials":727,"activeCount":142,"soonestReadout":732},[728],{"nctId":729,"briefTitle":730,"status":110,"phases":731,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":738},"NCT06015568","Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation",[84],"2028-11-04","2029-07-04","2023-09-01",172,[737],"Non-Small Cell Lung Cancer、EGFR Sensitive Mutation",[722,739],"Befotertinib: 75 mg or 100 mg Po QD",{"trials":741,"activeCount":12},[],{"trials":743,"activeCount":12},[],{"trials":745,"activeCount":12},[],{"trials":747,"activeCount":12},[],{"intervention":739,"totalTrials":142,"cells":749},{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":751,"activeCount":12},[],{"trials":753,"activeCount":142,"soonestReadout":732},[754],{"nctId":729,"briefTitle":730,"status":110,"phases":755,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":756,"interventions":757},[84],[737],[722,739],{"trials":759,"activeCount":12},[],{"trials":761,"activeCount":12},[],{"trials":763,"activeCount":12},[],{"trials":765,"activeCount":12},[],{"intervention":63,"totalTrials":142,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":769,"activeCount":12},[],{"trials":771,"activeCount":142,"soonestReadout":62},[772],{"nctId":60,"briefTitle":61,"status":110,"phases":773,"primaryCompletion":62,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":779},[84],"2026-04-03","2024-12-13",166,[778],"Non-Small Cell Lung Cancer With EGFR Mutation",[63,780,781],"Dose-Expansion (Phase Ib) CFT8919","Cohort-Expansion (Phase Ic) CFT8919",{"trials":783,"activeCount":12},[],{"trials":785,"activeCount":12},[],{"trials":787,"activeCount":12},[],{"trials":789,"activeCount":12},[],{"intervention":780,"totalTrials":142,"cells":791},{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":793,"activeCount":12},[],{"trials":795,"activeCount":142,"soonestReadout":62},[796],{"nctId":60,"briefTitle":61,"status":110,"phases":797,"primaryCompletion":62,"completion":774,"start":775,"enrollment":776,"conditions":798,"interventions":799},[84],[778],[63,780,781],{"trials":801,"activeCount":12},[],{"trials":803,"activeCount":12},[],{"trials":805,"activeCount":12},[],{"trials":807,"activeCount":12},[],{"intervention":781,"totalTrials":142,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":818,"PHASE3":820,"PHASE4":822,"NA":824},{"trials":811,"activeCount":12},[],{"trials":813,"activeCount":142,"soonestReadout":62},[814],{"nctId":60,"briefTitle":61,"status":110,"phases":815,"primaryCompletion":62,"completion":774,"start":775,"enrollment":776,"conditions":816,"interventions":817},[84],[778],[63,780,781],{"trials":819,"activeCount":12},[],{"trials":821,"activeCount":12},[],{"trials":823,"activeCount":12},[],{"trials":825,"activeCount":12},[],{"intervention":406,"totalTrials":21,"cells":827},{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":848,"PHASE4":858,"NA":869},{"trials":829,"activeCount":12},[],{"trials":831,"activeCount":12},[],{"trials":833,"activeCount":12},[834,844],{"nctId":835,"briefTitle":836,"status":123,"phases":837,"primaryCompletion":838,"completion":401,"start":839,"enrollment":840,"conditions":841,"interventions":842},"NCT01707329","Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment",[85],"2016-07","2012-09",180,[15],[406,843],"Icotinib+chemotherapy",{"nctId":398,"briefTitle":399,"status":123,"phases":845,"primaryCompletion":401,"completion":402,"start":403,"enrollment":237,"conditions":846,"interventions":847},[85],[32],[44,406],{"trials":849,"activeCount":12},[850,854],{"nctId":456,"briefTitle":457,"status":100,"phases":851,"primaryCompletion":459,"completion":460,"start":461,"enrollment":451,"conditions":852,"interventions":853},[86],[23],[44,406],{"nctId":465,"briefTitle":466,"status":123,"phases":855,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":856,"interventions":857},[86],[15],[44,406],{"trials":859,"activeCount":12},[860],{"nctId":861,"briefTitle":862,"status":123,"phases":863,"primaryCompletion":864,"completion":546,"start":865,"enrollment":237,"conditions":866,"interventions":867},"NCT01665417","Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma",[87],"2017-07","2012-08",[27,30],[868,406,406],"Experimental",{"trials":870,"activeCount":12},[],{"intervention":514,"totalTrials":142,"cells":872},{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":877,"PHASE3":879,"PHASE4":881,"NA":887},{"trials":874,"activeCount":12},[],{"trials":876,"activeCount":12},[],{"trials":878,"activeCount":12},[],{"trials":880,"activeCount":12},[],{"trials":882,"activeCount":12},[883],{"nctId":506,"briefTitle":507,"status":123,"phases":884,"primaryCompletion":316,"completion":509,"start":510,"enrollment":511,"conditions":885,"interventions":886},[87],[27,30],[514,44],{"trials":888,"activeCount":12},[],{"intervention":868,"totalTrials":142,"cells":890},{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":897,"PHASE4":899,"NA":905},{"trials":892,"activeCount":12},[],{"trials":894,"activeCount":12},[],{"trials":896,"activeCount":12},[],{"trials":898,"activeCount":12},[],{"trials":900,"activeCount":12},[901],{"nctId":861,"briefTitle":862,"status":123,"phases":902,"primaryCompletion":864,"completion":546,"start":865,"enrollment":237,"conditions":903,"interventions":904},[87],[27,30],[868,406,406],{"trials":906,"activeCount":12},[],{"intervention":908,"totalTrials":142,"cells":909},"Sequential and maintenance icotinib",{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":918,"NA":928},{"trials":911,"activeCount":12},[],{"trials":913,"activeCount":12},[],{"trials":915,"activeCount":12},[],{"trials":917,"activeCount":12},[],{"trials":919,"activeCount":12},[920],{"nctId":921,"briefTitle":922,"status":123,"phases":923,"primaryCompletion":864,"completion":864,"start":924,"enrollment":237,"conditions":925,"interventions":926},"NCT02194556","Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC",[87],"2014-07",[27,30],[908,927],"Maintenance icotinib",{"trials":929,"activeCount":12},[],{"intervention":927,"totalTrials":142,"cells":931},{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":946},{"trials":933,"activeCount":12},[],{"trials":935,"activeCount":12},[],{"trials":937,"activeCount":12},[],{"trials":939,"activeCount":12},[],{"trials":941,"activeCount":12},[942],{"nctId":921,"briefTitle":922,"status":123,"phases":943,"primaryCompletion":864,"completion":864,"start":924,"enrollment":237,"conditions":944,"interventions":945},[87],[27,30],[908,927],{"trials":947,"activeCount":12},[],{"intervention":949,"totalTrials":142,"cells":950},"Icotinib plus WBRT",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":968},{"trials":952,"activeCount":12},[],{"trials":954,"activeCount":12},[],{"trials":956,"activeCount":12},[],{"trials":958,"activeCount":12},[],{"trials":960,"activeCount":12},[961],{"nctId":962,"briefTitle":963,"status":123,"phases":964,"primaryCompletion":459,"completion":401,"start":382,"enrollment":965,"conditions":966,"interventions":967},"NCT01926171","Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases",[87],80,[32],[949],{"trials":969,"activeCount":12},[],{"intervention":971,"totalTrials":142,"cells":972},"D-0316",{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":979,"PHASE4":992,"NA":994},{"trials":974,"activeCount":12},[],{"trials":976,"activeCount":12},[],{"trials":978,"activeCount":12},[],{"trials":980,"activeCount":12},[981],{"nctId":982,"briefTitle":983,"status":100,"phases":984,"primaryCompletion":985,"completion":986,"start":987,"enrollment":988,"conditions":989,"interventions":990},"NCT04206072","D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC",[85,86],"2022-07-30","2025-07-15","2019-12-24",362,[18,365],[971,991],"Icotinib Hydrochloride",{"trials":993,"activeCount":12},[],{"trials":995,"activeCount":12},[],{"intervention":991,"totalTrials":142,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1010,"NA":1012},{"trials":999,"activeCount":12},[],{"trials":1001,"activeCount":12},[],{"trials":1003,"activeCount":12},[],{"trials":1005,"activeCount":12},[1006],{"nctId":982,"briefTitle":983,"status":100,"phases":1007,"primaryCompletion":985,"completion":986,"start":987,"enrollment":988,"conditions":1008,"interventions":1009},[85,86],[18,365],[971,991],{"trials":1011,"activeCount":12},[],{"trials":1013,"activeCount":12},[],{"intervention":483,"totalTrials":142,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1028,"NA":1030},{"trials":1017,"activeCount":12},[],{"trials":1019,"activeCount":12},[],{"trials":1021,"activeCount":12},[],{"trials":1023,"activeCount":12},[1024],{"nctId":475,"briefTitle":476,"status":100,"phases":1025,"primaryCompletion":478,"completion":383,"start":479,"enrollment":480,"conditions":1026,"interventions":1027},[86],[15],[44,483],{"trials":1029,"activeCount":12},[],{"trials":1031,"activeCount":12},[],{"intervention":635,"totalTrials":142,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1046,"NA":1048},{"trials":1035,"activeCount":12},[],{"trials":1037,"activeCount":12},[],{"trials":1039,"activeCount":12},[],{"trials":1041,"activeCount":12},[1042],{"nctId":625,"briefTitle":626,"status":123,"phases":1043,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":1044,"interventions":1045},[86],[633],[58,635],{"trials":1047,"activeCount":12},[],{"trials":1049,"activeCount":12},[],{"intervention":1051,"totalTrials":33,"cells":1052},"X-396",{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1090,"PHASE4":1092,"NA":1094},{"trials":1054,"activeCount":12},[],{"trials":1056,"activeCount":12},[],{"trials":1058,"activeCount":12},[1059,1070,1081],{"nctId":1060,"briefTitle":1061,"status":123,"phases":1062,"primaryCompletion":1063,"completion":1064,"start":1065,"enrollment":1066,"conditions":1067,"interventions":1069},"NCT04415320","X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases",[85],"2020-12","2021-06","2019-03-21",37,[1068,20],"Lung Cancer, Nonsmall Cell",[1051],{"nctId":1071,"briefTitle":1072,"status":123,"phases":1073,"primaryCompletion":1074,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1080},"NCT03608007","X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement",[85],"2020-03","2020-09","2018-06-15",69,[106,1079],"ROS1 Gene Rearrangement",[1051],{"nctId":1082,"briefTitle":1083,"status":123,"phases":1084,"primaryCompletion":1085,"completion":469,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1089},"NCT03215693","X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib",[85],"2020-03-09","2017-09-28",152,[18],[1051],{"trials":1091,"activeCount":12},[],{"trials":1093,"activeCount":12},[],{"trials":1095,"activeCount":12},[],{"intervention":1097,"totalTrials":142,"cells":1098},"MRX2843",{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1100,"activeCount":12},[],{"trials":1102,"activeCount":12},[],{"trials":1104,"activeCount":12},[1105],{"nctId":1106,"briefTitle":1107,"status":123,"phases":1108,"primaryCompletion":43,"completion":43,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1113},"NCT04946890","A Study of MRX2843 in Subjects With Relapsed\u002FRefractory Acute Myeloid Leukemia",[84,85],"2021-07-01",104,[1112],"Acute Myeloid Leukemia Leukemia",[1097],{"trials":1115,"activeCount":12},[],{"trials":1117,"activeCount":12},[],{"trials":1119,"activeCount":12},[],{"intervention":1121,"totalTrials":142,"cells":1122},"1-year treatment with icotinib",{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1124,"activeCount":12},[],{"trials":1126,"activeCount":12},[],{"trials":1128,"activeCount":12},[1129],{"nctId":1130,"briefTitle":1131,"status":123,"phases":1132,"primaryCompletion":315,"completion":1133,"start":1134,"enrollment":430,"conditions":1135,"interventions":1136},"NCT01929200","Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation",[85],"2017-08","2013-08",[32],[1121,1137],"2-year treatment with icotinib",{"trials":1139,"activeCount":12},[],{"trials":1141,"activeCount":12},[],{"trials":1143,"activeCount":12},[],{"intervention":1137,"totalTrials":142,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1147,"activeCount":12},[],{"trials":1149,"activeCount":12},[],{"trials":1151,"activeCount":12},[1152],{"nctId":1130,"briefTitle":1131,"status":123,"phases":1153,"primaryCompletion":315,"completion":1133,"start":1134,"enrollment":430,"conditions":1154,"interventions":1155},[85],[32],[1121,1137],{"trials":1157,"activeCount":12},[],{"trials":1159,"activeCount":12},[],{"trials":1161,"activeCount":12},[],{"intervention":1163,"totalTrials":142,"cells":1164},"Clofarabine",{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1182,"PHASE4":1184,"NA":1186},{"trials":1166,"activeCount":12},[],{"trials":1168,"activeCount":12},[],{"trials":1170,"activeCount":12},[1171],{"nctId":1172,"briefTitle":1173,"status":100,"phases":1174,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":1178,"conditions":1179,"interventions":1181},"NCT02544789","Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia",[85],"2011-11","2012-05","2009-06",44,[1180],"Acute Lymphoblastic Leukemia",[1163],{"trials":1183,"activeCount":12},[],{"trials":1185,"activeCount":12},[],{"trials":1187,"activeCount":12},[],{"intervention":843,"totalTrials":142,"cells":1189},{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1200,"PHASE4":1202,"NA":1204},{"trials":1191,"activeCount":12},[],{"trials":1193,"activeCount":12},[],{"trials":1195,"activeCount":12},[1196],{"nctId":835,"briefTitle":836,"status":123,"phases":1197,"primaryCompletion":838,"completion":401,"start":839,"enrollment":840,"conditions":1198,"interventions":1199},[85],[15],[406,843],{"trials":1201,"activeCount":12},[],{"trials":1203,"activeCount":12},[],{"trials":1205,"activeCount":12},[],{"intervention":1207,"totalTrials":142,"cells":1208},"Icotinib of routine dose",{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1210,"activeCount":12},[],{"trials":1212,"activeCount":12},[],{"trials":1214,"activeCount":12},[1215],{"nctId":1216,"briefTitle":1217,"status":123,"phases":1218,"primaryCompletion":315,"completion":838,"start":839,"enrollment":840,"conditions":1219,"interventions":1220},"NCT01690390","Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease",[85],[23],[1207,1221],"Icotinib of high dose",{"trials":1223,"activeCount":12},[],{"trials":1225,"activeCount":12},[],{"trials":1227,"activeCount":12},[],{"intervention":1221,"totalTrials":142,"cells":1229},{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1240,"PHASE4":1242,"NA":1244},{"trials":1231,"activeCount":12},[],{"trials":1233,"activeCount":12},[],{"trials":1235,"activeCount":12},[1236],{"nctId":1216,"briefTitle":1217,"status":123,"phases":1237,"primaryCompletion":315,"completion":838,"start":839,"enrollment":840,"conditions":1238,"interventions":1239},[85],[23],[1207,1221],{"trials":1241,"activeCount":12},[],{"trials":1243,"activeCount":12},[],{"trials":1245,"activeCount":12},[],{"intervention":1247,"totalTrials":142,"cells":1248},"Routine dose icotinib",{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1263,"PHASE4":1265,"NA":1267},{"trials":1250,"activeCount":12},[],{"trials":1252,"activeCount":12},[],{"trials":1254,"activeCount":12},[1255],{"nctId":1256,"briefTitle":1257,"status":123,"phases":1258,"primaryCompletion":439,"completion":401,"start":295,"enrollment":1259,"conditions":1260,"interventions":1261},"NCT02027090","High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease",[85],64,[15],[1247,1262],"Higher dose icotinib",{"trials":1264,"activeCount":12},[],{"trials":1266,"activeCount":12},[],{"trials":1268,"activeCount":12},[],{"intervention":1262,"totalTrials":142,"cells":1270},{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1281,"PHASE4":1283,"NA":1285},{"trials":1272,"activeCount":12},[],{"trials":1274,"activeCount":12},[],{"trials":1276,"activeCount":12},[1277],{"nctId":1256,"briefTitle":1257,"status":123,"phases":1278,"primaryCompletion":439,"completion":401,"start":295,"enrollment":1259,"conditions":1279,"interventions":1280},[85],[15],[1247,1262],{"trials":1282,"activeCount":12},[],{"trials":1284,"activeCount":12},[],{"trials":1286,"activeCount":12},[],{"intervention":1288,"totalTrials":142,"cells":1289},"Icotinib hydrochloride cream",{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1294,"PHASE3":1308,"PHASE4":1310,"NA":1312},{"trials":1291,"activeCount":12},[],{"trials":1293,"activeCount":12},[],{"trials":1295,"activeCount":12},[1296],{"nctId":1297,"briefTitle":1298,"status":1299,"phases":1300,"primaryCompletion":1301,"completion":1302,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1307},"NCT03222622","Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis","TERMINATED",[85],"2018-08-15","2018-10-26","2017-11-29",136,[1306],"Mild to Moderate Psoriasis",[1288],{"trials":1309,"activeCount":12},[],{"trials":1311,"activeCount":12},[],{"trials":1313,"activeCount":12},[],{"intervention":1315,"totalTrials":142,"cells":1316},"BPB-101",{"EARLY_PHASE1":1317,"PHASE1":1319,"PHASE2":1321,"PHASE3":1333,"PHASE4":1335,"NA":1337},{"trials":1318,"activeCount":12},[],{"trials":1320,"activeCount":12},[],{"trials":1322,"activeCount":12},[1323],{"nctId":1324,"briefTitle":1325,"status":123,"phases":1326,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1332},"NCT05869240","BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors",[84,85],"2025-08-02","2025-09-01","2023-05-16",388,[25],[1315],{"trials":1334,"activeCount":12},[],{"trials":1336,"activeCount":12},[],{"trials":1338,"activeCount":12},[],{"intervention":1340,"totalTrials":142,"cells":1341},"BPI-361175",{"EARLY_PHASE1":1342,"PHASE1":1344,"PHASE2":1346,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1343,"activeCount":12},[],{"trials":1345,"activeCount":12},[],{"trials":1347,"activeCount":12},[1348],{"nctId":1349,"briefTitle":1350,"status":123,"phases":1351,"primaryCompletion":1352,"completion":628,"start":1353,"enrollment":1354,"conditions":1355,"interventions":1356},"NCT05329298","A Phase 1\u002F2 Study of BPI-361175 in Subjects With Advanced Solid Tumors",[84,85],"2023-06-30","2021-07-21",90,[15],[1340],{"trials":1358,"activeCount":12},[],{"trials":1360,"activeCount":12},[],{"trials":1362,"activeCount":12},[],{"intervention":1364,"totalTrials":142,"cells":1365},"Icotinib with concurrent radiotherapy",{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1367,"activeCount":12},[],{"trials":1369,"activeCount":12},[],{"trials":1371,"activeCount":12},[1372],{"nctId":1373,"briefTitle":1374,"status":123,"phases":1375,"primaryCompletion":1376,"completion":1377,"start":1378,"enrollment":430,"conditions":1379,"interventions":1380},"NCT02215356","Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer",[85],"2018-08","2019-02","2014-08",[15],[1364,1381],"Chemoradiotherapy",{"trials":1383,"activeCount":12},[],{"trials":1385,"activeCount":12},[],{"trials":1387,"activeCount":12},[],{"intervention":1381,"totalTrials":142,"cells":1389},{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1391,"activeCount":12},[],{"trials":1393,"activeCount":12},[],{"trials":1395,"activeCount":12},[1396],{"nctId":1373,"briefTitle":1374,"status":123,"phases":1397,"primaryCompletion":1376,"completion":1377,"start":1378,"enrollment":430,"conditions":1398,"interventions":1399},[85],[15],[1364,1381],{"trials":1401,"activeCount":12},[],{"trials":1403,"activeCount":12},[],{"trials":1405,"activeCount":12},[],{"intervention":1407,"totalTrials":248,"cells":1408},"BPI-9016M",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1431,"PHASE3":1433,"PHASE4":1435,"NA":1437},{"trials":1410,"activeCount":12},[],{"trials":1412,"activeCount":12},[1413,1423],{"nctId":1414,"briefTitle":1415,"status":100,"phases":1416,"primaryCompletion":1417,"completion":1418,"start":1419,"enrollment":530,"conditions":1420,"interventions":1422},"NCT02478866","Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors",[84],"2017-06-30","2017-11","2015-08-11",[1421],"Solid Tumors",[1407],{"nctId":1424,"briefTitle":1425,"status":123,"phases":1426,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":965,"conditions":1429,"interventions":1430},"NCT02929290","Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC",[84],"2024-11","2017-03-01",[15],[1407],{"trials":1432,"activeCount":12},[],{"trials":1434,"activeCount":12},[],{"trials":1436,"activeCount":12},[],{"trials":1438,"activeCount":12},[],{"intervention":311,"totalTrials":248,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1453,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1442,"activeCount":12},[],{"trials":1444,"activeCount":12},[1445,1449],{"nctId":301,"briefTitle":302,"status":123,"phases":1446,"primaryCompletion":294,"completion":304,"start":305,"enrollment":306,"conditions":1447,"interventions":1448},[84],[308],[310,311],{"nctId":313,"briefTitle":302,"status":123,"phases":1450,"primaryCompletion":315,"completion":316,"start":317,"enrollment":306,"conditions":1451,"interventions":1452},[84],[308],[310,311],{"trials":1454,"activeCount":12},[],{"trials":1456,"activeCount":12},[],{"trials":1458,"activeCount":12},[],{"trials":1460,"activeCount":12},[],{"intervention":299,"totalTrials":142,"cells":1462},{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1471,"PHASE3":1473,"PHASE4":1475,"NA":1477},{"trials":1464,"activeCount":12},[],{"trials":1466,"activeCount":12},[1467],{"nctId":290,"briefTitle":291,"status":123,"phases":1468,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":1469,"interventions":1470},[84],[15],[44,299],{"trials":1472,"activeCount":12},[],{"trials":1474,"activeCount":12},[],{"trials":1476,"activeCount":12},[],{"trials":1478,"activeCount":12},[],{"intervention":1480,"totalTrials":142,"cells":1481},"0.5% Icotinib hydrochloride cream",{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1499,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1483,"activeCount":12},[],{"trials":1485,"activeCount":12},[1486],{"nctId":1487,"briefTitle":1488,"status":100,"phases":1489,"primaryCompletion":1490,"completion":1490,"start":1491,"enrollment":1492,"conditions":1493,"interventions":1495},"NCT02801435","Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis",[84],"2017-06-08","2016-09-17",41,[1494],"Psoriasis",[1480,1496,1497,1498],"1.0% Icotinib hydrochloride cream","2.0% Icotinib hydrochloride cream","4.0% Icotinib hydrochloride cream",{"trials":1500,"activeCount":12},[],{"trials":1502,"activeCount":12},[],{"trials":1504,"activeCount":12},[],{"trials":1506,"activeCount":12},[],{"intervention":1496,"totalTrials":142,"cells":1508},{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1510,"activeCount":12},[],{"trials":1512,"activeCount":12},[1513],{"nctId":1487,"briefTitle":1488,"status":100,"phases":1514,"primaryCompletion":1490,"completion":1490,"start":1491,"enrollment":1492,"conditions":1515,"interventions":1516},[84],[1494],[1480,1496,1497,1498],{"trials":1518,"activeCount":12},[],{"trials":1520,"activeCount":12},[],{"trials":1522,"activeCount":12},[],{"trials":1524,"activeCount":12},[],{"intervention":1497,"totalTrials":142,"cells":1526},{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1528,"activeCount":12},[],{"trials":1530,"activeCount":12},[1531],{"nctId":1487,"briefTitle":1488,"status":100,"phases":1532,"primaryCompletion":1490,"completion":1490,"start":1491,"enrollment":1492,"conditions":1533,"interventions":1534},[84],[1494],[1480,1496,1497,1498],{"trials":1536,"activeCount":12},[],{"trials":1538,"activeCount":12},[],{"trials":1540,"activeCount":12},[],{"trials":1542,"activeCount":12},[],{"intervention":1498,"totalTrials":142,"cells":1544},{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1553,"PHASE3":1555,"PHASE4":1557,"NA":1559},{"trials":1546,"activeCount":12},[],{"trials":1548,"activeCount":12},[1549],{"nctId":1487,"briefTitle":1488,"status":100,"phases":1550,"primaryCompletion":1490,"completion":1490,"start":1491,"enrollment":1492,"conditions":1551,"interventions":1552},[84],[1494],[1480,1496,1497,1498],{"trials":1554,"activeCount":12},[],{"trials":1556,"activeCount":12},[],{"trials":1558,"activeCount":12},[],{"trials":1560,"activeCount":12},[],{"intervention":1562,"totalTrials":142,"cells":1563},"BPI-28592",{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1577,"PHASE3":1579,"PHASE4":1581,"NA":1583},{"trials":1565,"activeCount":12},[],{"trials":1567,"activeCount":12},[1568],{"nctId":1569,"briefTitle":1570,"status":123,"phases":1571,"primaryCompletion":628,"completion":628,"start":1572,"enrollment":1573,"conditions":1574,"interventions":1576},"NCT05302843","A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors",[84],"2021-03-22",40,[1575],"Metastasis, Neoplasm",[1562],{"trials":1578,"activeCount":12},[],{"trials":1580,"activeCount":12},[],{"trials":1582,"activeCount":12},[],{"trials":1584,"activeCount":12},[],{"intervention":1586,"totalTrials":142,"cells":1587},"BPI-421286",{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1589,"activeCount":12},[],{"trials":1591,"activeCount":12},[1592],{"nctId":1593,"briefTitle":1594,"status":123,"phases":1595,"primaryCompletion":1596,"completion":1596,"start":1597,"enrollment":965,"conditions":1598,"interventions":1601},"NCT05315180","A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors",[84],"2023-07-31","2021-08-24",[1599,1600],"Malignant Neoplasms","Metastatic Cancer",[1586],{"trials":1603,"activeCount":12},[],{"trials":1605,"activeCount":12},[],{"trials":1607,"activeCount":12},[],{"trials":1609,"activeCount":12},[],{"intervention":1611,"totalTrials":142,"cells":1612},"[14C]D-0316 suspension",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1626,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1614,"activeCount":12},[],{"trials":1616,"activeCount":12},[1617],{"nctId":1618,"briefTitle":1619,"status":123,"phases":1620,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":28,"conditions":1623,"interventions":1625},"NCT04464551","The Absorption, Metabolism and Excretion of [14C]D-0316 in Human",[84],"2021-08","2020-12-05",[1624],"Advanced or Metastatic Non-small Cell Lung",[1611],{"trials":1627,"activeCount":12},[],{"trials":1629,"activeCount":12},[],{"trials":1631,"activeCount":12},[],{"trials":1633,"activeCount":12},[],{"intervention":1635,"totalTrials":142,"cells":1636},"BPI-442096",{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1651,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1638,"activeCount":12},[],{"trials":1640,"activeCount":12},[1641],{"nctId":1642,"briefTitle":1643,"status":123,"phases":1644,"primaryCompletion":1645,"completion":1646,"start":1647,"enrollment":1648,"conditions":1649,"interventions":1650},"NCT05369312","Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients",[84],"2024-05-01","2025-05-01","2022-06",230,[25,15,308,227],[1635],{"trials":1652,"activeCount":12},[],{"trials":1654,"activeCount":12},[],{"trials":1656,"activeCount":12},[],{"trials":1658,"activeCount":12},[],{"intervention":1660,"totalTrials":142,"cells":1661},"BPI-15086",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1674,"PHASE3":1676,"PHASE4":1678,"NA":1680},{"trials":1663,"activeCount":12},[],{"trials":1665,"activeCount":12},[1666],{"nctId":1667,"briefTitle":1668,"status":100,"phases":1669,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":114,"conditions":1672,"interventions":1673},"NCT02914990","Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients",[84],"2019-03-07","2016-12-29",[18],[1660],{"trials":1675,"activeCount":12},[],{"trials":1677,"activeCount":12},[],{"trials":1679,"activeCount":12},[],{"trials":1681,"activeCount":12},[],{"intervention":1683,"totalTrials":142,"cells":1684},"1% icotinib hydrochloride cream",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1698,"PHASE3":1700,"PHASE4":1702,"NA":1704},{"trials":1686,"activeCount":12},[],{"trials":1688,"activeCount":12},[1689],{"nctId":1690,"briefTitle":1691,"status":100,"phases":1692,"primaryCompletion":1693,"completion":1693,"start":1694,"enrollment":263,"conditions":1695,"interventions":1696},"NCT02574091","Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients",[84],"2017-02-19","2015-11-26",[1494],[1683,1697],"2% icotinib hydrochloride cream",{"trials":1699,"activeCount":12},[],{"trials":1701,"activeCount":12},[],{"trials":1703,"activeCount":12},[],{"trials":1705,"activeCount":12},[],{"intervention":1697,"totalTrials":142,"cells":1707},{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1709,"activeCount":12},[],{"trials":1711,"activeCount":12},[1712],{"nctId":1690,"briefTitle":1691,"status":100,"phases":1713,"primaryCompletion":1693,"completion":1693,"start":1694,"enrollment":263,"conditions":1714,"interventions":1715},[84],[1494],[1683,1697],{"trials":1717,"activeCount":12},[],{"trials":1719,"activeCount":12},[],{"trials":1721,"activeCount":12},[],{"trials":1723,"activeCount":12},[],{"intervention":1725,"totalTrials":142,"cells":1726},"Ensartinib with fed or fasting",{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1739,"PHASE3":1741,"PHASE4":1743,"NA":1745},{"trials":1728,"activeCount":12},[],{"trials":1730,"activeCount":12},[1731],{"nctId":1732,"briefTitle":1733,"status":100,"phases":1734,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":306,"conditions":1737,"interventions":1738},"NCT03510611","A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.",[84],"2018-08-02","2018-03-12",[18],[1725],{"trials":1740,"activeCount":12},[],{"trials":1742,"activeCount":12},[],{"trials":1744,"activeCount":12},[],{"trials":1746,"activeCount":12},[],{"intervention":1748,"totalTrials":142,"cells":1749},"BPI-452080",{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1751,"activeCount":12},[],{"trials":1753,"activeCount":12},[1754],{"nctId":1755,"briefTitle":1756,"status":123,"phases":1757,"primaryCompletion":1758,"completion":1759,"start":1760,"enrollment":1761,"conditions":1762,"interventions":1765},"NCT05843305","A Study of BPI-452080 in Subjects With Solid Tumors",[84],"2025-03-25","2025-10-31","2023-04-28",87,[25,1763,1764],"Renal Cell Carcinoma","Von Hippel-Lindau Disease",[1748],{"trials":1767,"activeCount":12},[],{"trials":1769,"activeCount":12},[],{"trials":1771,"activeCount":12},[],{"trials":1773,"activeCount":12},[],{"intervention":1775,"totalTrials":142,"cells":1776},"BPI-21668",{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1790,"PHASE3":1792,"PHASE4":1794,"NA":1796},{"trials":1778,"activeCount":12},[],{"trials":1780,"activeCount":12},[1781],{"nctId":1782,"briefTitle":1783,"status":123,"phases":1784,"primaryCompletion":1785,"completion":1786,"start":1787,"enrollment":375,"conditions":1788,"interventions":1789},"NCT05341570","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668",[84],"2024-01-31","2025-01-31","2022-01-19",[652],[1775],{"trials":1791,"activeCount":12},[],{"trials":1793,"activeCount":12},[],{"trials":1795,"activeCount":12},[],{"trials":1797,"activeCount":12},[],{"intervention":1799,"totalTrials":142,"cells":1800},"BPI-3016",{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1816,"PHASE3":1818,"PHASE4":1820,"NA":1822},{"trials":1802,"activeCount":12},[],{"trials":1804,"activeCount":12},[1805],{"nctId":1806,"briefTitle":1807,"status":123,"phases":1808,"primaryCompletion":1809,"completion":1810,"start":1811,"enrollment":1812,"conditions":1813,"interventions":1815},"NCT03188848","Dose Escalating Study of BPI-3016 in Healthy Subjects",[84],"2019-07","2019-12","2017-05-24",63,[1814],"Healthy Subject",[1799],{"trials":1817,"activeCount":12},[],{"trials":1819,"activeCount":12},[],{"trials":1821,"activeCount":12},[],{"trials":1823,"activeCount":12},[]]